The clinical trial sponsored by the Institute of Liver and Biliary Sciences aims to investigate the effects of a high protein diet on hepatic steatosis and mitochondrial dysfunction in MAFLD patients, a condition increasingly prevalent in India. Given the rising incidence of MAFLD and the lack of established dietary guidelines, this study could provide pivotal data that may influence dietary recommendations and therapeutic strategies in metabolic diseases. The findings could position the sponsor as a leader in nutritional interventions for liver diseases, potentially opening avenues for partnerships with dietary supplement manufacturers and healthcare providers focused on metabolic health. The competitive landscape includes other dietary interventions, but this study's focus on high protein diets may differentiate it in the market.